ReCode Therapeutics
MENLO PARK, CA · Biotechnology, Healthcare, Health Care · 35 employees
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
Funding history
- Funding Round — $29.4M — Oct 2025
- Funding Round — $29.0M — Sep 2025
- Funding Round — $15.0M — Nov 2024
- Funding Round — $259.8M — Sep 2023
- Series series b — Undisclosed — Sep 2023
Recent signals
- Oct 23, 2025: Raised $29.4M
- Sep 29, 2025: Raised $29.0M
- Nov 18, 2024: Raised $15.0M
- Sep 28, 2023: Raised $259.8M
- Sep 19, 2023: Raised funding in Series series b
- Jul 10, 2023: ReCode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs
- Jan 27, 2023: Raised $210.0M
- Jul 06, 2022: Raised $160.0M
See plans & pricing → Track ReCode Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.